文献速递头颈外科耳科与耳神经

HPV相关口咽鳞状细胞癌辅助治疗降阶试验中的听力结局

Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma.
PubMed 文献 · Otolaryngol Head Neck Surg · 2023-01-19

本研究为回顾性队列研究,比较MINT试验中接受降阶辅助治疗(42 Gy放疗±单次100 mg/m²顺铂)的HPV相关口咽鳞状细胞癌患者与接受标准辅助治疗(60-66 Gy放疗+最多三次100 mg/m²顺铂)的历史队列的耳毒性发生率。MINT队列耳毒性率为5%(3/58耳),历史队列为46%(25/54耳),校正后OR为0.05(95%CI 0.01-0.31)。

要点

  • MINT队列耳毒性率5%(3/58耳),历史队列46%(25/54耳)。
  • MINT队列耳毒性风险较历史队列降低95%(校正OR 0.05,95%CI 0.01-0.31)。
  • 频率≥3 kHz时估计边际均值阈值偏移差异有统计学和临床意义。

核心结论

  • MINT试验中的降阶辅助治疗使HPV相关口咽鳞状细胞癌患者的耳毒性低于标准辅助治疗。

研究设计与样本

  • 回顾性队列研究,单学术中心;比较MINT试验(前瞻性2期试验,手术+风险调整降阶辅助治疗:42 Gy放疗单独或联合单次100 mg/m²顺铂)入组的成年HPV相关口咽鳞状细胞癌患者与接受标准辅助治疗(60-66 Gy放疗+最多三次100 mg/m²顺铂)的历史队列。

主要发现

  • MINT队列分析29例患者(58耳),历史队列分析27例患者(54耳)。
  • 耳毒性率MINT队列为5%(n=3/58耳),历史队列为46%(n=25/54耳),差值41%(95%CI 27%-56%)。
  • MINT队列患者耳毒性风险较历史队列降低95%(校正OR 0.05,95%CI 0.01-0.31)。
  • 频率≥3 kHz时估计边际均值阈值偏移差异有统计学和临床意义。

关键数值与推荐

  • 耳毒性定义为常见不良事件评价标准v5.0≥2级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore whether deintensification of adjuvant therapy reduces ototoxicity among patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC). STUDY DESIGN: Retrospective cohort study. SETTING: Single academic center. METHODS: The ototoxicity rate among adult patients with HPV-related OPSCC enrolled in the Minimalist Trial (MINT), a prospective phase 2 trial of surgery followed by risk-adjusted deintensified adjuvant therapy (42 Gy radiation given alone or with a single 100 mg/m2 dose of cisplatin), was compared to that among a historical cohort treated with standard adjuvant therapy (60-66 Gy radiation with up to three 100 mg/m2 doses of cisplatin). Ototoxicity was defined as Common Terminology Criteria for Adverse Events v5.0 ≥ Grade 2. Mixed model analysis was performed to investigate the association between deintensified adjuvant therapy and treatment-related hearing loss. RESULTS: A total of 29 patients (58 ears) were analyzed in the MINT cohort, and 27 patients (54 ears) in the historical cohort. The ototoxicity rate was 5% (n = 3/58 ears) in the MINT cohort and 46% (n = 25/54 ears) in the historical cohort (difference, 41%; 95% confidence interval [CI] = 27%-56%). Patients in the MINT cohort demonstrated a 95% decrease in risk of ototoxicity compared to those in the historical cohort (adjusted odds ratio: 0.05, 95% CI = 0.01-0.31). Differences in estimated marginal mean threshold shifts were statistically and clinically significant at frequencies ≥ 3 kHz. CONCLUSION: The deintensified adjuvant therapy given in MINT led to less ototoxicity than standard adjuvant therapy among patients with HPV-related OPSCC.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Lee DS, Mahal RS, Tharakan T, et al. Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV-Related Oropharyngeal Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2023. PMID: 36939390. doi:10.1002/ohn.182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。